

The B-vitamin network with ramification to the tryptophan-niacin pathway



Midttun Ø^{1,*}, Kvalheim, G^{1,2} and Ueland PM^{2,3}

¹Bevital A/S, Bergen Norway.

²Section for Pharmacology, Institute of Medicine, University of Bergen, Norway.

³Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway

*Corresponding author, email nkjbm@uib.no

Background: Vitamins B2, B6, folate and B12 function as coenzymes in the one-carbon metabolism, and vitamins B2 and B6 also in the tryptophan-niacin (vitamin B3) pathway (Figure 1). Metabolism of tryptophan through this pathway is increased in inflammation. One form of niacin, nicotinamide, is converted to N¹-methylnicotinamide by using S-adenosylmethionine as methyl donor, thereby connecting one-carbon metabolism with the tryptophan-niacin pathway. In addition, published data on plasma concentrations of vitamin B3 forms (non-supplemented), quinolinic acid and N¹-methylnicotinamide are sparse.

Aim: To include additional tryptophan-niacin pathway metabolites in an established HPLC-MS/MS assay that measures vitamins B2 and B6, several tryptophan metabolites, and inflammation markers. Further, to use a panel of plasma biomarkers to investigate relations between B-vitamin status, one-carbon metabolism, the tryptophan-niacin pathway, and inflammation.

Results: We included the tryptophan-niacin pathway metabolites quinolinic acid, nicotinamide, nicotinic acid and N¹-methylnicotinamide in an established HPLC-MS/MS assay (1). 60 µL of plasma was deproteinized and the supernatant injected onto a stable-bond C8 column. The chromatographic run-time was 5 minutes (Figure 2). The detector was a triple quadrupole mass spectrometer fitted with electrospray probe and operated in positive multiple reaction monitoring mode. A total of 21 plasma/serum analytes (Table 1) are measured by the assay, and assay capacity is 172 samples/day. Method validation characteristics (Table 2) make this assay suitable for use in routine analysis of endogenous plasma concentrations (Table 3).

Conclusions: The expanded assay will be used to analyse plasma samples from biobanks. Combined with other assays, this will allow investigation of the metabolic network involving of B-vitamins, one-carbon metabolism, the tryptophan-niacin pathway and inflammation.

Acknowledgements: Marit Krokeide is thanked for excellent technical assistance in assay development.

References:

(1) Midttun et al., Rapid Communications in Mass Spectrometry vol. 23, 2009, p. 1371.




Figure 1. One-carbon metabolism (left) and the tryptophan - niacin pathway (right).

SAM function as methyl donor for the conversion of nicotinamide to N¹-methylnicotinamide. Coenzymes are shown in blue ellipses. Abbreviations: THF, tetrahydrofolate; CH₂THF, methylenetetrahydrofolate; CH₃THF, methyltetrahydrofolate; SAM, S-adenosylmethionine, SAH, S-adenosylhomocysteine, NAD, nicotinamide adenine dinucleotide; B2, vitamin B2; B6, vitamin B6; B12, vitamin B12.

Table 1. Analytes included in the assay.

Vitamin B2 forms:	Vitamin B6 forms:	Other:	Tryptophan metabolism:
Riboflavin	Pyridoxal 5'-phosphate		Tryptophan
Flavin mononucleotide	Pyridoxal		Kynurenine
	4-pyridoxic acid		Kynurenic acid
	Pyridoxine		Anthranilic acid
	Pyridoxamine		3-hydroxykynurenine
	Cystathionine		Xanthurenic acid
	Cotinine		3-hydroxyanthranilic acid
	Neopterin		Quinolinic acid
			Nicotinamide
			Nicotinic acid
			N ¹ -methylnicotinamide

Table 2. Method validation characteristics of the new analytes in the assay.

Analyte	Within-day CV (%) ^a	Between-day CV (%) ^a	Recovery (%) ^b	Linear range (nM)	Linearity (r ²)	LOD (nM)
Quinolinic acid	7.0 - 7.5	7.2 - 10.3	88 - 96	1.6 - 4000	0.993	1.6
Nicotinamide	10.0 - 12.2	8.7 - 11.8	105 - 109	20 - 16000	0.987	20
Nicotinic acid	9.9 - 17.3	10.7 - 14.8	106 - 112	20 - 8000	0.995	20
N ¹ -methylnicotinamide	4.8 - 6.6	6.8 - 8.5	92 - 98	5 - 16000	0.997	5.0

^aThe CV experiments (N=18) were performed at three concentrations (low, medium and high) for each analyte. Low was an unspiked plasma pool having concentrations of 269.6 nM quinolinic acid, 116.8 nM nicotinamide, 67.9 nM nicotinic acid and 67.0 nM N¹-methylnicotinamide, medium was spiked with 1000 nM quinolinic acid, nicotinamide and N¹-methylnicotinamide and 100 nM nicotinic acid, while high was spiked with 2000 nM quinolinic acid, nicotinamide and N¹-methylnicotinamide and 200 nM nicotinic acid.

^bRecovery was calculated from the CV experiments.

Table 3. Plasma concentrations (nM)^a.

Analyte	Median	(5,95 percentile)
Quinolinic acid	225.5	(133.6, 383.8)
Nicotinamide	177.4	(91.9, 388.3)
Nicotinic acid	64.3	(42.9, 101.3)
N ¹ -methylnicotinamide	68.5	(27.1, 220.5)

^aMeasured in 172 presumed healthy adult humans.




Figure 2. Chromatogram.

Chromatogram of unspiked plasma pool (Table 2). Abbreviations: cps, counts per second; QUIN, quinolinic acid; NAM, nicotinamide; NA, nicotinic acid; MNAM, N¹-methylnicotinamide.